| 28.33 -0.66 (-2.28%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 44.94 |
1-year : | 52.44 |
| Resists | First : | 38.48 |
Second : | 44.9 |
| Pivot price | 31.66 |
|||
| Supports | First : | 28.1 |
Second : | 23.37 |
| MAs | MA(5) : | 29.59 |
MA(20) : | 33.63 |
| MA(100) : | 40.58 |
MA(250) : | 34.15  |
|
| MACD | MACD : | -3.7 |
Signal : | -3.5 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 5.2 |
| RSI | RSI(14): 20.9 |
|||
| 52-week | High : | 52.93 | Low : | 23.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RAPP ] has closed above bottom band by 2.5%. Bollinger Bands are 12.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.34 - 29.58 | 29.58 - 29.74 |
| Low: | 27.61 - 27.87 | 27.87 - 28.05 |
| Close: | 27.99 - 28.39 | 28.39 - 28.66 |
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Sun, 11 Oct 2026
Which Brain Pathways Is Rapport Therapeutics Trying to Tune? - Kalkine Media
Fri, 25 Sep 2026
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com India
Thu, 24 Sep 2026
RAPP Form 4 Filings - Rapport Therapeutics, Inc. SEC Form 4 - Stock Titan
Wed, 09 Sep 2026
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Nigeria
Tue, 11 Aug 2026
Rapport Therapeutics (RAPP) CEO Abraham Ceesay sells 51,499 shares via 10b5-1 plan - Stock Titan
Thu, 25 Jun 2026
RAPP Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 3.8 (%) |
| Held by Institutions | 109 (%) |
| Shares Short | 3,190 (K) |
| Shares Short P.Month | 2,230 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.81 |
| Profit Margin | 0 % |
| Operating Margin | -767.6 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -40 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.46 |
| Sales Per Share | 0.41 |
| EBITDA (p.s.) | -3.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -9.35 |
| PEG Ratio | 0 |
| Price to Book value | 3.21 |
| Price to Sales | 67.96 |
| Price to Cash Flow | -14.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|